Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY5625575 · 1 trial · 2 indications
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY5625575 (Part A) - Single Dose Healthy | EXPERIMENTAL | Single escalating doses of LY5625575 administered orally in healthy participants. |
| Placebo (Part A) - Single Dose Healthy | PLACEBO_COMPARATOR | Single dose of placebo administered orally in healthy participants. |
| LY5625575 (Part B) - Multiple Dose Healthy | EXPERIMENTAL | Two or more doses of LY5625575 administered orally in healthy participants. |
| Placebo (Part B) - Multiple Dose Healthy | PLACEBO_COMPARATOR | Two or more doses of placebo administered orally in healthy participants. |
| LY5625575 (Part C) - Multiple Dose Elevated hsCRP | EXPERIMENTAL | Two or more doses of LY5625575 administered orally in participants with elevated high-sensitivity C-reactive protein (hsCRP). |
| Placebo (Part C) - Multiple Dose Elevated hsCRP | PLACEBO_COMPARATOR | Two or more doses of placebo administered orally in participants with elevated hsCRP. |
| LY5625575 (Part D) - Multiple Dose Healthy Japanese | EXPERIMENTAL | Two or more doses of LY5625575 administered orally in healthy Japanese participants. |
| Placebo (Part D) - Multiple Dose Healthy Japanese | PLACEBO_COMPARATOR | Two or more doses of placebo administered orally in healthy Japanese participants |
| LY5625575 (Part E) - Multiple Dose Healthy Chinese | EXPERIMENTAL | Two or more doses of LY5625575 administered orally in healthy Chinese participants. |
| Placebo (Part E) - Multiple Dose Healthy Chinese | PLACEBO_COMPARATOR | Two or more doses of placebo administered orally in healthy Chinese participants. |
| Name | Type | Description |
|---|---|---|
| LY5625575 | DRUG | Administered orally. |
| Placebo | DRUG | Administered orally. |
Inclusion Criteria: * All Parts: * Individuals not of childbearing potential may participate in this trial. * Individuals assigned male at birth may participate in this trial. * Healthy as defined by * the absence of clinically significant illness and surgery within 35 days prior to fir...